SCHEMBL8962772

SCHEMBL8962772

CCCCC(C)OC(=S)CS(=O)(=O)Nc1c(C(C)C)cccc1C(C)C

nearest known ligand 0.48

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8962495 0.95 SOAT1 (0.50) SOAT1
SCHEMBL8962485 0.95 SOAT1 (0.50) SOAT1
SCHEMBL8962541 0.95 SOAT1 (0.50) SOAT1
SCHEMBL8962520 0.95 SOAT1 (0.50) SOAT1
SCHEMBL8962356 0.95 SOAT1 (0.50) SOAT1
SCHEMBL8962730 0.84
SCHEMBL8962709 0.78 SOAT1 (0.48) SOAT1
SCHEMBL8962427 0.78
SCHEMBL8962536 0.76 SOAT1 (0.44) SOAT1
SCHEMBL8962453 0.73 MAPT (0.42) SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996019446-A1 β-CARBOXY SULFONAMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1996-06-27 WO disclosed
US-5491170-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-02-13 US disclosed